AstraZeneca PLC (AZN)vsIradimed Co (IRMD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
IRMD
Iradimed Co
$83.44
-0.32%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 69983% more annual revenue ($58.74B vs $83.81M). IRMD leads profitability with a 26.8% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.54. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
IRMD
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-81.7%
Fair Value
$56.73
Current Price
$83.44
$26.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 11.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 47.8x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while IRMD is a growth play — different risk/reward profiles.
IRMD carries more volatility with a beta of 1.12 — expect wider price swings.
IRMD is growing revenue faster at 17.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 60/100), backed by strong 17.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?